Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders
Jurgen Sota, Luciana Breda, Maria Pia Paroli, Soad Hashad, Alejandra de‐la‐Torre, Silvana Guerriero, Abdurrahman Tufan, Juanita Cardona-López, María José Altamar-García, Saverio La Bella, Antonio Vitale, Edoardo Biancalana, Emanuela Del Giudice, Francesca Minoia, Sulaiman M. Al‐Mayouf, Bruno Frediani, Luca Cantarini, Claudia Fabiani
Abstract
To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported.The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.